Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers
British Journal of Cancer, 09/26/07
Ota, T., et al. - In a study to determine the survival rate, incidence of late complications, and incidence of second cancers when radiation therapy alone is used for carcinoma of the uterine cervix, it was found that this method of radiation therapy alone for locally advanced carcinoma of the uterine cervix is effective, with low incidences of late complications and second cancers
Methods- 1495 patients with squamous cell carcinoma of the uterine cervix (stages I-IV) were treated with radiation therapy alone
- Radiation therapy consisted of a combination of high-dose-rate intracavitary brachytherapy and external beam radiotherapy
- Cumulative 5-year survival rates for stages Ib, II, and III/IVa carcinoma were 93.5, 77.0, and 60.3%, respectively
- 10-year survival rates were 90.9, 74.5, and 56.1%, respectively
- Local control rates for stages Ib, II, and III/IVa carcinoma were 92.0, 79.4 and 64.2%, respectively
- 5.5% of patients suffered grade III/IV or V (fatal) complications
- A second cancer developed in 0.87% of patients
- Second cancers were observed most frequently in the rectum (5 cases), colon (3 cases), and uterine body (2 cases)
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
The Lancet, 11/23/09
Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway
Molecular Cancer, 11/20/09
Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors
Journal of Cancer Research & Clinical Oncology, 11/20/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


